Barger L, El Naggar O, Ha B, Romano G
Cancer Metastasis Rev. 2024; 44(1):9.
PMID: 39609320
PMC: 11604825.
DOI: 10.1007/s10555-024-10230-6.
Brunetti J, Kitsera M, Munoz-Fontela C, Rodriguez E
Viruses. 2023; 15(1).
PMID: 36680271
PMC: 9866769.
DOI: 10.3390/v15010228.
Endsley J, Huante M, Naqvi K, Gelman B, Endsley M
Retrovirology. 2021; 18(1):14.
PMID: 34134725
PMC: 8206883.
DOI: 10.1186/s12977-021-00559-z.
Martinov T, McKenna K, Hong Tan W, Collins E, Kehret A, Linton J
Front Immunol. 2021; 12:643852.
PMID: 33692812
PMC: 7938325.
DOI: 10.3389/fimmu.2021.643852.
Marsden M
Retrovirology. 2020; 17(1):7.
PMID: 32252791
PMC: 7137310.
DOI: 10.1186/s12977-020-00516-2.
Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection.
Liberatore R, Mastrocola E, Cassella E, Schmidt F, Willen J, Voronin D
Elife. 2019; 8.
PMID: 31644426
PMC: 6874478.
DOI: 10.7554/eLife.49875.
Immune Activations and Viral Tissue Compartmentalization During Progressive HIV-1 Infection of Humanized Mice.
Su H, Cheng Y, Sravanam S, Mathews S, Gorantla S, Poluektova L
Front Immunol. 2019; 10:340.
PMID: 30873181
PMC: 6403174.
DOI: 10.3389/fimmu.2019.00340.
Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
Lin A, Balazs A
Retrovirology. 2018; 15(1):66.
PMID: 30285769
PMC: 6167872.
DOI: 10.1186/s12977-018-0449-7.
From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.
Kudalkar S, Beloor J, Quijano E, Spasov K, Lee W, Cisneros J
Proc Natl Acad Sci U S A. 2017; 115(4):E802-E811.
PMID: 29279368
PMC: 5789948.
DOI: 10.1073/pnas.1717932115.
The mouse viral outgrowth assay: avatars for the detection of HIV-1 reservoirs.
Metcalf Pate K, Blankson J
Retrovirology. 2017; 14(1):52.
PMID: 29157283
PMC: 5697021.
DOI: 10.1186/s12977-017-0376-z.
TALEN gene editing takes aim on HIV.
Benjamin R, Berges B, Solis-Leal A, Igbinedion O, Strong C, Schiller M
Hum Genet. 2016; 135(9):1059-70.
PMID: 27170155
PMC: 5002248.
DOI: 10.1007/s00439-016-1678-2.
Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis.
Campos N, Myburgh R, Garcel A, Vautrin A, Lapasset L, Nadal E
Retrovirology. 2015; 12:30.
PMID: 25889234
PMC: 4422473.
DOI: 10.1186/s12977-015-0159-3.
Impacts of humanized mouse models on the investigation of HIV-1 infection: illuminating the roles of viral accessory proteins in vivo.
Yamada E, Yoshikawa R, Nakano Y, Misawa N, Koyanagi Y, Sato K
Viruses. 2015; 7(3):1373-90.
PMID: 25807049
PMC: 4379576.
DOI: 10.3390/v7031373.
Studies of retroviral infection in humanized mice.
Marsden M, Zack J
Virology. 2015; 479-480:297-309.
PMID: 25680625
PMC: 4424058.
DOI: 10.1016/j.virol.2015.01.017.
Humanized mouse models of epstein-barr virus infection and associated diseases.
Fujiwara S, Matsuda G, Imadome K
Pathogens. 2014; 2(1):153-76.
PMID: 25436886
PMC: 4235711.
DOI: 10.3390/pathogens2010153.
Humanized mouse models for HIV-1 infection of the CNS.
Honeycutt J, Sheridan P, Matsushima G, Garcia J
J Neurovirol. 2014; 21(3):301-9.
PMID: 25366661
PMC: 4418936.
DOI: 10.1007/s13365-014-0299-6.
Generation of improved humanized mouse models for human infectious diseases.
Brehm M, Wiles M, Greiner D, Shultz L
J Immunol Methods. 2014; 410:3-17.
PMID: 24607601
PMC: 4155027.
DOI: 10.1016/j.jim.2014.02.011.
Humanized mice: novel model for studying mechanisms of human immune-based therapies.
Gonzalez L, Strbo N, Podack E
Immunol Res. 2013; 57(1-3):326-34.
PMID: 24248605
PMC: 3966553.
DOI: 10.1007/s12026-013-8471-2.
PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads.
Seung E, Dudek T, Allen T, Freeman G, Luster A, Tager A
PLoS One. 2013; 8(10):e77780.
PMID: 24204962
PMC: 3804573.
DOI: 10.1371/journal.pone.0077780.
Humanized mice for the study of infectious diseases.
Brehm M, Jouvet N, Greiner D, Shultz L
Curr Opin Immunol. 2013; 25(4):428-35.
PMID: 23751490
PMC: 3775881.
DOI: 10.1016/j.coi.2013.05.012.